Durable near-complete response to Anti-PD-1 checkpoint immunotherapy in a refractory malignant solitary fibrous tumor of the pleura

James T. Boothe, G. Thomas Budd, Matthew B. Smolkin, Patrick C. Ma

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Solitary fibrous tumor of the pleura is a rare and usually benign primary neoplasm arising from mesenchymal cells of the submesothelial tissue. We present here the case of a patient diagnosed with CD34-positive advanced malignant solitary fibrous tumor of the pleura whose disease failed to respond to combination cytotoxic chemotherapy agents, but demonstrated a prompt near-complete response to checkpoint blockade treatment using the anti-programmed death (PD)-1 monoclonal antibody pembrolizumab, based on tumor molecular profiling revealing tumoral expression positivity for both programmed death-ligand 1 (PD-L1) and PD-1. The patient experienced minimal adverse effects from the treatment with durable favorable response lasting up to cycle 26.

Original languageEnglish (US)
Pages (from-to)998-1005
Number of pages8
JournalCase Reports in Oncology
Volume10
Issue number3
DOIs
StatePublished - Nov 16 2017

All Science Journal Classification (ASJC) codes

  • Oncology

Fingerprint Dive into the research topics of 'Durable near-complete response to Anti-PD-1 checkpoint immunotherapy in a refractory malignant solitary fibrous tumor of the pleura'. Together they form a unique fingerprint.

Cite this